our Premium Content: News alerts, weekly reports and conference planners

GENE:

DDR2 (Discoidin domain receptor 2)

News alerts, weekly reports and conference planners

Frequency of expression and prognostic implications of emerging molecular targets in pulmonary squamous cell carcinoma. (PubMed, Indian J Pathol Microbiol)

The targets evaluated have potential drugs currently under trial phase. This may help to define the subgroup for use of targeted therapy in NSCLC-SCC and in designing new treatment protocols.

1 month ago

Journal

KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1) • DDR2 (Discoidin domain receptor 2)

KRAS mutation • MET overexpression • FGFR mutation

Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis. (PubMed, Discov Oncol)

The MBRG-based model effectively predicts BLCA prognosis, integrates mechanisms of basement membrane remodeling, EMT, and immune suppression, and identifies DDR2 and SERPINF1 in CAFs as potential targets for personalized therapy.

1 month ago

Journal • IO biomarker

TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • DDR2 (Discoidin domain receptor 2) • SLIT2 (Slit Guidance Ligand 2)

dasatinib • LY2109761 • WNT974

Genomic Profiling of Highly Aggressive Musculoskeletal Sarcomas Identifies Potential Therapeutic Targets: A Single-Center Experience. (PubMed, Cancers (Basel))

Early access to genomic analyses, routine germline assessment, and broad gene panels would help in identifying possible targeted drugs with sufficient evidence of activity beneficial to each patient. In the clinical management of advanced sarcoma patients, when analyzing cost-effectiveness and sustainability, the role of the Molecular Tumor Board in the governance of the complexity introduced by mutational oncology should be considered.

1 month ago

Journal

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PMS2 (PMS1 protein homolog 2) • MUC16 (Mucin 16, Cell Surface Associated) • NOTCH4 (Notch 4) • RHOA (Ras homolog family member A) • BARD1 (BRCA1 Associated RING Domain 1) • CCND3 (Cyclin D3) • DDR2 (Discoidin domain receptor 2) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A)

Archer® VariantPlex® Solid Tumor Kit

2ms

Decoding collagen cues: the interplay of integrins and discoidin domain receptors in health and disease. (PubMed, J Biomed Sci)

This comprehension is crucial for developing novel therapeutic strategies. Emerging evidence suggests that combined targeting DDRs and integrins can synergistically overcome ECM-mediated therapy resistance, enhance immune infiltration, and reprogram pathological microenvironments, offering a promising approach for treating fibrosis and collagen-rich cancers.

2 months ago

Review • Journal

DDR2 (Discoidin domain receptor 2)

2ms

Drug Development. (PubMed, Alzheimers Dement)

We developed candidate therapeutics for PSP using ASOs that silence novel therapeutic targets discovered in our systems based cross-species screening. We showed that our ASOs have low toxicity and confirmed target engagement at both mRNA and protein levels in vitro. The results suggest a favorable preclinical profile of our ASO leads that warrants additional investigations. Importantly, PSP shares congruent pathophysiological changes with other tauopathies, such as Alzheimer's disease. These common perturbed pathways indicate that our ASOs can be potentially repurposed for multiple neurodegenerative tauopathies.

2 months ago

Journal

DDR2 (Discoidin domain receptor 2)

3ms

Nationwide comprehensive genomic profiling defines the genomic landscape of hepatocellular carcinoma across etiologies. (PubMed, Sci Rep)

The absence of a relationship between HRR alterations and TMB suggests distinct biological mechanisms. Liquid biopsy remains a reliable option when tissues are unavailable in managing patients with HCC.

3 months ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • TERT (Telomerase Reverse Transcriptase) • DDR2 (Discoidin domain receptor 2) • AXIN1 (Axin 1)

3ms

Drug repositioning of regorafenib for renal cell carcinoma identifies DDR2‑associated sensitivity in ACHN models. (PubMed, Korean J Physiol Pharmacol)

Clinically, higher DDR2 associated with inferior overall survival in The Cancer Genome Atlas papillary cohort (KIRP), with no consistent association in the clear cell cohort (KIRC). Across in vitro, in vivo, and in silico analyses, DDR2-high papillary contexts exhibit preferential regorafenib sensitivity, nominating DDR2-enriched papillary RCC for biomarker-guided repurposing and motivating protein-level and genetic validation.

3 months ago

Journal

DDR2 (Discoidin domain receptor 2)

Stivarga (regorafenib)

3ms

Transmembrane association of DDR1 and DDR2 mediated by Leucine zipper motifs. (PubMed, Magn Reson Lett)

These findings demonstrated the TMD as a critical mediator of DDRs oligomerization and revealed their interaction patterns within membrane. Our study advances the understanding of DDR signaling regulation and highlights transmembrane domain interactions as potential targets for modulating DDR-related pathologies.

3 months ago

Journal

DDR2 (Discoidin domain receptor 2)

3ms

PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance. (PubMed, Ther Adv Med Oncol)

A genomic expression analysis performed in Cohort #3 (n = 35) showed that a downregulation in the PI3K/AKT/mTOR pathway was mainly evident in the GP group of patients. This integrated multi-step analysis identified potentially altered pathways with a biological impact on squamous-NSCLC oncogenesis, suggesting that the PI3KCA/mTOR pathway could affect the prognosis of resected SCC patients through both genomic aberrations and impaired expression.

3 months ago

Journal

SMAD4 (SMAD family member 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDR2 (Discoidin domain receptor 2)

PIK3CA mutation

4ms

Collagen Signaling via DDR1 Exacerbates Barriers to Macromolecular Drug Delivery in a 3D Model of Pancreatic Cancer Fibrosis. (PubMed, Small)

Downstream of DDR, the involvement of the PI3K/AKT/mTOR pathway is demonstrated, particularly alternative mTOR complexes involving MEAK7 and GIT1. Altogether, the results show in vitro that DDR1-mediated collagen signaling exacerbates the fibrotic barrier and may be targeted to enhance macromolecular drug delivery in PDAC.

4 months ago

Journal

DDR2 (Discoidin domain receptor 2)

4ms

Integration of machine learning to reveal the correlation between ferroptosis and M2 macrophages in head and neck squamous cell carcinoma. (PubMed, Discov Oncol)

In this study, we constructed an MFRS model to predict patient prognosis and therapeutic response. This study also preliminarily reveals the roles of M2Ms and ferroptosis in HNSCC patients and provides potentially novel insight for treatment.

4 months ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • SLC3A2 (Solute Carrier Family 3 Member 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • DDR2 (Discoidin domain receptor 2) • NOX4 (NADPH Oxidase 4) • PRKCA (Protein Kinase C Alpha) • ALOX12B (Arachidonate 12-Lipoxygenase) • ENPP2 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 2)